Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dor BioPharma has entered into a one-year exclusive option with the president and Fellows of Harvard College to license analogues of anthrax toxin for prospective use in vaccines against anthrax, a potentially fatal disease caused by the spore-forming, gram-positive bacterium Bacillus anthracis.
Subscribe to our email newsletter
The option, which was obtained through negotiation with the Harvard University’s Office of Technology Development, encompasses an issued US patent that covers engineered variants of protective antigen (PA) developed in the Harvard Medical School laboratory of John Collier. PA is the principal determinant of protective immunity to anthrax and is being developed for second- and third-generation anthrax vaccines.
Dor believes that it will be able to develop the Collier anthrax vaccine into one with an improved stability profile, an issue that has proven challenging in the development of other anthrax vaccines.
Christopher Schaber, president and CEO of Dor, said: “We believe that the engineered PA variants can be used in platform technologies for delivery of single use or combination biodefense vaccines and will be useful for generating stable vaccines that induce antibodies in fewer doses than the conventional AVA vaccine or other rPA vaccines currently under development.”